Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FDA posts Mevacor briefing documents

FDA will ask an advisory panel on Thursday whether new data from Merck (MRK) support that over-the-counter customers can

Read the full 194 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE